Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

Kód výsledku v IS VaVaI

<a href="https://www.isvavai.cz/riv?ss=detail&h=RIV%2F00216208%3A11110%2F14%3A10286238" target="_blank" >RIV/00216208:11110/14:10286238 - isvavai.cz</a>

Nalezeny alternativní kódy

RIV/00023728:_____/14:#0004009

Výsledek na webu

<a href="http://dx.doi.org/10.1007/s10198-014-0592-6" target="_blank" >http://dx.doi.org/10.1007/s10198-014-0592-6</a>

DOI - Digital Object Identifier

<a href="http://dx.doi.org/10.1007/s10198-014-0592-6" target="_blank" >10.1007/s10198-014-0592-6</a>

Jazyk výsledku

angličtina

Název v původním jazyce

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

Popis výsledku v původním jazyce

Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania andSlovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collec

Název v anglickém jazyce

Biological therapy in inflammatory rheumatic diseases: issues in Central and Eastern European countries

Popis výsledku anglicky

Biological drugs revolutionized the treatment of inflammatory rheumatic diseases. Access to treatment presents substantial variability across Europe. The economic level of a particular country as well as administrative restrictions have been proved as determining factors of biological drug uptake. The objective of this paper was to provide an overview of biological treatment in six selected Central and Eastern European (CEE) countries, namely in the Bulgaria, Czech Republic, Hungary, Poland, Romania andSlovakia. The literature is summarized with regard to the epidemiology, disease burden and use of biological agents in rheumatoid arthritis, psoriatic arthritis and ankylosing spondylitis. Moreover, an estimate is provided on the prevalence and number of patients with biological treatment based on international and local sources. In view of the limited availability of information and uncertainty in data, there is an urgent need for development of systematic and comprehensive data collec

Druh

J_x - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)

CEP obor

FE - Ostatní obory vnitřního lékařství

OECD FORD obor

—

Projekt

—

Návaznosti

V - Vyzkumna aktivita podporovana z jinych verejnych zdroju

Rok uplatnění

2014

Kód důvěrnosti údajů

S - Úplné a pravdivé údaje o projektu nepodléhají ochraně podle zvláštních právních předpisů

Název periodika

European Journal of Health Economics

ISSN

1618-7598

e-ISSN

—

Svazek periodika

15

Číslo periodika v rámci svazku

Suppl. 1

Stát vydavatele periodika

DE - Spolková republika Německo

Počet stran výsledku

9

Strana od-do

"S35"-"S43"

Kód UT WoS článku

000344664600005

EID výsledku v databázi Scopus

—